Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Using points for low value items can waste your rewards. Discover smarter choices to make the most of your credit card benefits.
24,708 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Oil-price volatility and strong cash-flow signals helped Occidental Petroleum stock jumped on Monday. Learn the drive...
SpaceX grabs headlines, but a smaller IPO could offer bigger upside for patient investors. This guide walks you throu...
Insider moves can mislead, but context matters. This article explains why Nick Khan’s 9,589 share sale isn’t a warnin...
Understanding James River (JRVR) earnings means decoding insurance results, investment income, and risk management. T...
Investors are buzzing about great news amazon stock as Amazon leans into cloud, ads, and AI. This guide explains the ...
Semiconductors retreat while Apple climbs, creating an unusual market dynamic. This article breaks down what the chip...
Chime stock down since its June IPO has traders weighing risk and opportunity. A new $11 million stake from a promine...
A big jump in one segment reveals more about private lending than a flashy corporate spin-off. Here’s how to read the...
blockbuster numbers aren’t just hoopla. when avengers: doomsday racks up $16.5m in first-day presales, it highlights...
Looking for serious cash back without paying a yearly fee? In 2023, several no annual fee cards combined strong categ...
Cathie Wood is known for bold bets, but recently her moves hint at bargain-hunting in big-name tech. This article bre...